pamidronate has been researched along with Hyperparathyroidism in 37 studies
Hyperparathyroidism: A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It is characterized by HYPERCALCEMIA and BONE RESORPTION, eventually leading to bone diseases. PRIMARY HYPERPARATHYROIDISM is caused by parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. SECONDARY HYPERPARATHYROIDISM is increased PTH secretion in response to HYPOCALCEMIA, usually caused by chronic KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We report a case in which a patient with tertiary hyperparathyroidism and refractory hypercalcemia who was not a surgical candidate was managed with the bisphosphonate pamidronate." | 7.75 | Hypercalcemia associated with tertiary hyperparathyroidism managed conservatively with pamidronate in a hemodialysis patient. ( Canada, RB; Czosnowski, LM; Hudson, JQ, 2009) |
| "We describe the use of pamidronate to control marked hypercalcemia in an extremely premature infant with neonatal hyperparathyroidism that resulted from an inactivating mutation (R220W) of the calcium-sensing receptor." | 7.74 | Neonatal hyperparathyroidism and pamidronate therapy in an extremely premature infant. ( Cole, DE; Fox, L; Kidd, A; Murdoch, J; Pringle, KP; Sadowsky, J; Wiltshire, E, 2007) |
| "We commend the short-term use of pamidronate in neonatal severe hyperparathyroidism to treat extreme hypercalcaemia and halt hyperparathyroid-driven skeletal demineralisation in preparation for parathyroidectomy." | 7.72 | Neonatal severe hyperparathyroidism: genotype/phenotype correlation and the use of pamidronate as rescue therapy. ( Cheetham, T; Cranston, T; Kurzawinski, T; Pearce, S; Spitz, L; Thakker, R; van't Hoff, WG; Waller, S, 2004) |
| "Intravenous pamidronate disodium has been used successfully in the treatment of malignancy-associated hypercalcemia and Paget's disease of bone." | 7.69 | Intravenous pamidronate for hypercalcemia of primary hyperparathyroidism. ( Graves, L; Tal, A, 1996) |
| "Pamidronate (aminopropylidene diphosphonate, APD) is known to be an effective agent in lowering plasma calcium in cancer associated hypercalcaemia and in primary hyperparathyroidism." | 7.68 | [Combination therapy with pamidronate and calcitonin in hypercalcemic crisis caused by primary hyperparathyroidism]. ( Christensen, JH; Kristiansen, JH, 1992) |
| "Nine patients (median age, 81 years) with primary hyperparathyroidism were treated with intravenous infusions of disodium pamidronate (APD), which is a bisphosphonate drug." | 7.68 | Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism. ( Jansson, S; Lindstedt, G; Lundberg, PA; Tisell, LE, 1991) |
| "Treatment with pamidronate resulted in a higher BMC of the lumbar spine than in the untreated animals, with elevated concentrations of hPTH." | 5.28 | Pamidronate reduces PTH-mediated bone loss in a gene transfer model of hyperparathyroidism in rats. ( Dobrolet, NC; Mitlak, BH; Neer, RM; Nussbaum, SR; Rodda, CP; Von Deck, MD, 1991) |
| " We report a case in which a patient with tertiary hyperparathyroidism and refractory hypercalcemia who was not a surgical candidate was managed with the bisphosphonate pamidronate." | 3.75 | Hypercalcemia associated with tertiary hyperparathyroidism managed conservatively with pamidronate in a hemodialysis patient. ( Canada, RB; Czosnowski, LM; Hudson, JQ, 2009) |
| "We commend the short-term use of pamidronate in neonatal severe hyperparathyroidism to treat extreme hypercalcaemia and halt hyperparathyroid-driven skeletal demineralisation in preparation for parathyroidectomy." | 3.72 | Neonatal severe hyperparathyroidism: genotype/phenotype correlation and the use of pamidronate as rescue therapy. ( Cheetham, T; Cranston, T; Kurzawinski, T; Pearce, S; Spitz, L; Thakker, R; van't Hoff, WG; Waller, S, 2004) |
| "25 mmol/L external Ca2+, 200 mumol/L gallium nitrate inhibited PTH release from preparations of primary and uremic hyperparathyroidism by 14% and 22%, respectively." | 3.69 | Effects of the antihypercalcemic drugs gallium nitrate and pamidronate on hormone release of pathologic human parathyroid cells. ( Akerström, G; Gylfe, E; Rastad, J; Ridefelt, P, 1995) |
| "Intravenous pamidronate disodium has been used successfully in the treatment of malignancy-associated hypercalcemia and Paget's disease of bone." | 3.69 | Intravenous pamidronate for hypercalcemia of primary hyperparathyroidism. ( Graves, L; Tal, A, 1996) |
| "Pamidronate (aminopropylidene diphosphonate, APD) is known to be an effective agent in lowering plasma calcium in cancer associated hypercalcaemia and in primary hyperparathyroidism." | 3.68 | [Combination therapy with pamidronate and calcitonin in hypercalcemic crisis caused by primary hyperparathyroidism]. ( Christensen, JH; Kristiansen, JH, 1992) |
| "Nine patients (median age, 81 years) with primary hyperparathyroidism were treated with intravenous infusions of disodium pamidronate (APD), which is a bisphosphonate drug." | 3.68 | Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism. ( Jansson, S; Lindstedt, G; Lundberg, PA; Tisell, LE, 1991) |
| "Indomethacin was effective in only one of five patients to whom it was given, and EHDP was effective also in only one of five patients." | 2.65 | Comparative study of available medical therapy for hypercalcemia of malignancy. ( Heath, DA; Mundy, GR; Wilkinson, R, 1983) |
| "Pamidronate was then administered sc (0." | 1.37 | Calcitropic hormones and IGF-I are influenced by dietary protein. ( Ammann, P; Brennan, TC; Dayer, R; Dubois-Ferrière, V; Rizzoli, R, 2011) |
| "By inhibiting bone resorption, bisphosphonate administration caused transient normalization of calcemia, associated with improved FIM, at a significantly higher level than in untreated patients (+16." | 1.32 | A single bisphosphonate infusion is associated with improved functional capacity in elderly subjects with primary hyperparathyroidism. ( Ammann, P; Herter-Clavel, C; Lubrano, A; Rizzoli, R, 2003) |
| "Primary hyperparathyroidism is usually associated with normal or elevated serum 1,25-dihydroxyvitamin D [1,25(OH)2D] levels." | 1.29 | Inhibition of 1,25(OH)2D production by hypercalcemia in osteitis fibrosa cystica: influence on parathyroid hormone secretion and hungry bone disease. ( Brossard, JH; D'Amour, P; Garon, J; Gascon-Barré, M; Lepage, R, 1993) |
| "Treatment with pamidronate normalized serum calcium concentration and induced a complete biochemical remission." | 1.28 | Paget's disease with osteolytic lesions: combining medical and surgical treatments. ( Bloem, RM; Brumsen, C; Papapoulos, SE, 1992) |
| "Treatment with pamidronate resulted in a higher BMC of the lumbar spine than in the untreated animals, with elevated concentrations of hPTH." | 1.28 | Pamidronate reduces PTH-mediated bone loss in a gene transfer model of hyperparathyroidism in rats. ( Dobrolet, NC; Mitlak, BH; Neer, RM; Nussbaum, SR; Rodda, CP; Von Deck, MD, 1991) |
| "The hypercalcemia was corrected by a single intravenous dose of (3-amino-1-hydroxypropylidene)-1,1-diphosphonate (15 mg), allowing parathyroidectomy to be performed electively and on a well patient." | 1.27 | Aminohydroxypropylidene diphosphonate treatment of hypercalcemic crisis due to primary hyperparathyroidism. ( Evans, RA, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (16.22) | 18.7374 |
| 1990's | 17 (45.95) | 18.2507 |
| 2000's | 11 (29.73) | 29.6817 |
| 2010's | 3 (8.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jain, N | 1 |
| Reilly, RF | 1 |
| Czosnowski, LM | 1 |
| Hudson, JQ | 1 |
| Canada, RB | 1 |
| Dubois-Ferrière, V | 1 |
| Brennan, TC | 1 |
| Dayer, R | 1 |
| Rizzoli, R | 2 |
| Ammann, P | 2 |
| Hoi, WH | 1 |
| Leow, MK | 1 |
| Sule, A | 1 |
| Lee, HY | 1 |
| Mmed, TA | 1 |
| Tay, JC | 1 |
| Buysschaert, M | 1 |
| Cosyns, JP | 1 |
| Barreto, L | 1 |
| Jadoul, M | 1 |
| Herter-Clavel, C | 1 |
| Lubrano, A | 1 |
| Waller, S | 1 |
| Kurzawinski, T | 1 |
| Spitz, L | 1 |
| Thakker, R | 1 |
| Cranston, T | 1 |
| Pearce, S | 1 |
| Cheetham, T | 1 |
| van't Hoff, WG | 1 |
| Jansson, S | 2 |
| Morgan, E | 1 |
| Räkel, A | 1 |
| Brossard, JH | 2 |
| Patenaude, JV | 1 |
| Albert, C | 1 |
| Nassif, E | 1 |
| Cantor, T | 1 |
| Rousseau, L | 1 |
| D'Amour, P | 2 |
| Duque, G | 1 |
| Segal, R | 1 |
| Wise, F | 1 |
| Bianco, J | 1 |
| Manouras, A | 1 |
| Toutouzas, KG | 1 |
| Markogiannakis, H | 1 |
| Lagoudianakis, E | 1 |
| Papadima, A | 1 |
| Antonakis, PT | 1 |
| Kafiri, G | 1 |
| Bramis, I | 1 |
| Fox, L | 1 |
| Sadowsky, J | 1 |
| Pringle, KP | 1 |
| Kidd, A | 1 |
| Murdoch, J | 1 |
| Cole, DE | 1 |
| Wiltshire, E | 1 |
| Mundy, GR | 2 |
| Wilkinson, R | 1 |
| Heath, DA | 1 |
| Delmas, PD | 2 |
| Meunier, PJ | 1 |
| van Breukelen, FJ | 1 |
| Bijvoet, OL | 1 |
| Frijlink, WB | 1 |
| Sleeboom, HP | 1 |
| Mulder, H | 1 |
| van Oosterom, AT | 1 |
| Ridefelt, P | 1 |
| Gylfe, E | 1 |
| Akerström, G | 1 |
| Rastad, J | 1 |
| Kotzmann, H | 1 |
| Svoboda, T | 1 |
| Bernecker, P | 1 |
| Clodi, M | 1 |
| Woloszczuk, W | 1 |
| Niederle, B | 1 |
| Waldhäusl, W | 1 |
| Luger, A | 1 |
| Garon, J | 1 |
| Lepage, R | 1 |
| Gascon-Barré, M | 1 |
| Rosenmund, A | 1 |
| Tal, A | 1 |
| Graves, L | 1 |
| Bonde, M | 1 |
| Garnero, P | 1 |
| Fledelius, C | 1 |
| Qvist, P | 1 |
| Christiansen, C | 1 |
| Malberti, F | 1 |
| Farina, M | 1 |
| Imbasciati, E | 1 |
| Coutaz, M | 1 |
| Morisod, J | 1 |
| Vanamo, R | 1 |
| Brumsen, C | 1 |
| Bloem, RM | 1 |
| Papapoulos, SE | 1 |
| Weatherall, M | 1 |
| Christensen, JH | 1 |
| Kristiansen, JH | 1 |
| Tabarin, A | 1 |
| Raynaud, S | 1 |
| Martigne, C | 1 |
| Roger, P | 1 |
| Mitlak, BH | 1 |
| Rodda, CP | 1 |
| Von Deck, MD | 1 |
| Dobrolet, NC | 1 |
| Neer, RM | 1 |
| Nussbaum, SR | 1 |
| Tisell, LE | 1 |
| Lindstedt, G | 1 |
| Lundberg, PA | 1 |
| Schmidli, RS | 1 |
| Wilson, I | 1 |
| Espiner, EA | 1 |
| Richards, AM | 1 |
| Donald, RA | 1 |
| Canivet, JL | 1 |
| Damas, P | 1 |
| Lamy, M | 1 |
| Fleisch, H | 1 |
| Evans, RA | 1 |
| Leunissen, KM | 1 |
| Vismans, FJ | 1 |
| van Leendert, RJ | 1 |
| van Hooff, JP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420] | Phase 1 | 4 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for pamidronate and Hyperparathyroidism
| Article | Year |
|---|---|
Hungry bone syndrome.
Topics: Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitriol; Calcium; Diphosphonates; Hum | 2017 |
[Hypercalcemia as an emergency].
Topics: Calcitonin; Calcium; Diphosphonates; Emergencies; Fluid Therapy; Furosemide; Humans; Hypercalcemia; | 1993 |
[The elderly patient and primary hyperparathyroidism].
Topics: Age Distribution; Age Factors; Aged; Aged, 80 and over; Diagnosis, Differential; Diphosphonates; Fem | 2000 |
[Biphosphonate as a therapeutic drug--experimental studies and clinical application].
Topics: Animals; Calcinosis; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Hyperpar | 1985 |
2 trials available for pamidronate and Hyperparathyroidism
| Article | Year |
|---|---|
Comparative study of available medical therapy for hypercalcemia of malignancy.
Topics: Administration, Oral; Adult; Aged; Calcium; Clinical Trials as Topic; Diphosphonates; Etidronic Acid | 1983 |
Aminopropylidine diphosphonate (APD) in mild primary hyperparathyroidism: effect on clinical status.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Calcium; Diphosphonates; Female; Humans; Hyperparath | 1990 |
31 other studies available for pamidronate and Hyperparathyroidism
| Article | Year |
|---|---|
Hypercalcemia associated with tertiary hyperparathyroidism managed conservatively with pamidronate in a hemodialysis patient.
Topics: Aged; Calcium; Diphosphonates; Humans; Hypercalcemia; Hyperparathyroidism; Kidney Failure, Chronic; | 2009 |
Calcitropic hormones and IGF-I are influenced by dietary protein.
Topics: Animals; Bone and Bones; Bone Resorption; Calcitriol; Calcium; Caseins; Dietary Proteins; Diphosphon | 2011 |
Hyperparathyroidism due to eutopic PTH secretion from an ectopic intrathymic parathyroid cyst.
Topics: Biomarkers; Biopsy; Calcitonin; Calcium; Choristoma; Diphosphonates; Diuretics; Female; Fluid Therap | 2011 |
Pamidronate-induced tubulointerstitial nephritis with Fanconi syndrome in a patient with primary hyperparathyroidism.
Topics: Aged; Biopsy, Needle; Diphosphonates; Fanconi Syndrome; Follow-Up Studies; Humans; Hyperparathyroidi | 2003 |
A single bisphosphonate infusion is associated with improved functional capacity in elderly subjects with primary hyperparathyroidism.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antimetabolites; Bone and Bones; Bone Resorptio | 2003 |
Neonatal severe hyperparathyroidism: genotype/phenotype correlation and the use of pamidronate as rescue therapy.
Topics: Antineoplastic Agents; Dehydration; Diphosphonates; DNA Mutational Analysis; Female; Genotype; Human | 2004 |
Biochemical effects from treatment with bisphosphonate and surgery in patients with primary hyperparathyroidism.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Diphosphonates; Female; Homeostasis; Human | 2004 |
Overproduction of an amino-terminal form of PTH distinct from human PTH(1-84) in a case of severe primary hyperparathyroidism: influence of medical treatment and surgery.
Topics: Adenoma; Antineoplastic Agents; Calcium; Chromatography, High Pressure Liquid; Diphosphonates; Fluid | 2005 |
Chronic hypercalcemia as a reversible cause of cognitive impairment: improvement after a single administration of pamidronate.
Topics: Aged; Chronic Disease; Cognition Disorders; Diphosphonates; Female; Humans; Hypercalcemia; Hyperpara | 2005 |
Intracystic hemorrhage in a mediastinal cystic adenoma causing parathyrotoxic crisis.
Topics: Adenoma; Adult; Bone Density Conservation Agents; Cystadenoma; Diphosphonates; Diuretics; Fluid Ther | 2008 |
Neonatal hyperparathyroidism and pamidronate therapy in an extremely premature infant.
Topics: Diphosphonates; Fatal Outcome; Female; Humans; Hyperparathyroidism; Infant; Infant, Newborn; Infant, | 2007 |
[Diphosphonates in the treatment of hypercalcemia].
Topics: Bone Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Hyperparathyr | 1984 |
Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium.
Topics: Adult; Aged; Bone Resorption; Calcium; Diphosphonates; Female; Humans; Hypercalcemia; Hyperparathyro | 1982 |
Effects of the antihypercalcemic drugs gallium nitrate and pamidronate on hormone release of pathologic human parathyroid cells.
Topics: Adult; Aged; Aged, 80 and over; Calcium; Cytoplasm; Diphosphonates; Gallium; Humans; Hypercalcemia; | 1995 |
[Disodium pamidronate (APD) in therapy of hypercalcemia in primary hyperparathyroidism].
Topics: Aged; Aged, 80 and over; Calcium; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; | 1994 |
Evaluation and treatment of hypercalcemia.
Topics: Adenoma; Aged; Bone Neoplasms; Carcinoma, Squamous Cell; Diagnosis, Differential; Diphosphonates; Fe | 1994 |
Inhibition of 1,25(OH)2D production by hypercalcemia in osteitis fibrosa cystica: influence on parathyroid hormone secretion and hungry bone disease.
Topics: Adenoma; Alkaline Phosphatase; Bone Resorption; Calcitonin; Calcitriol; Calcium; Calcium Carbonate; | 1993 |
Intravenous pamidronate for hypercalcemia of primary hyperparathyroidism.
Topics: Aged; Calcium; Diphosphonates; Female; Humans; Hypercalcemia; Hyperparathyroidism; Infusions, Intrav | 1996 |
Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen.
Topics: Adult; Alendronate; Amino Acid Sequence; Antibodies; Biomarkers; Bone Resorption; Collagen; Collagen | 1997 |
The PTH-calcium curve and the set point of calcium in primary and secondary hyperparathyroidism.
Topics: Calcium; Diphosphonates; Humans; Hyperparathyroidism; Hypocalcemia; Ions; Osmolar Concentration; Pam | 1999 |
[Only the indication will lead to the therapy].
Topics: Aged; Diphosphonates; Humans; Hyperparathyroidism; Osteoclasts; Pamidronate; Patient Selection; Trea | 2000 |
Paget's disease with osteolytic lesions: combining medical and surgical treatments.
Topics: Combined Modality Therapy; Diphosphonates; Femur; Humans; Hyperparathyroidism; Male; Middle Aged; Os | 1992 |
Pamidronate use in two cases of hypercalcaemia secondary to hyperparathyroidism.
Topics: Aged; Diphosphonates; Female; Humans; Hypercalcemia; Hyperparathyroidism; Pamidronate | 1992 |
[Combination therapy with pamidronate and calcitonin in hypercalcemic crisis caused by primary hyperparathyroidism].
Topics: Aged; Calcitonin; Diphosphonates; Drug Therapy, Combination; Female; Humans; Hypercalcemia; Hyperpar | 1992 |
[Use of aminopropydilene diphosphonate in a case of primary hyperparathyroidism].
Topics: Diphosphonates; Female; Humans; Hyperparathyroidism; Middle Aged; Pamidronate | 1992 |
Pamidronate.
Topics: Clinical Trials as Topic; Diphosphonates; Humans; Hypercalcemia; Hyperparathyroidism; Neoplasms; Ost | 1992 |
Pamidronate reduces PTH-mediated bone loss in a gene transfer model of hyperparathyroidism in rats.
Topics: Absorptiometry, Photon; Animals; Bone Density; Bone Resorption; Diphosphonates; Hyperparathyroidism; | 1991 |
Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism.
Topics: Adolescent; Aged; Aged, 80 and over; Diphosphonates; Female; Humans; Hypercalcemia; Hyperparathyroid | 1991 |
Posttraumatic parathyroid crisis and severe hypercalcemia treated with intravenous bisphosphonate (APD). Case report.
Topics: Abdominal Injuries; Acute Disease; Brain Concussion; Diphosphonates; Female; Humans; Hypercalcemia; | 1990 |
Aminohydroxypropylidene diphosphonate treatment of hypercalcemic crisis due to primary hyperparathyroidism.
Topics: Adult; Diphosphonates; Humans; Hypercalcemia; Hyperparathyroidism; Male; Pamidronate | 1987 |
Successful treatment of persistent posttransplant hyperparathyroidism with diphosphonate.
Topics: Bone and Bones; Calcium; Diphosphonates; Female; Humans; Hyperparathyroidism; Male; Middle Aged; Pam | 1986 |